JP2020518571A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020518571A5 JP2020518571A5 JP2019558778A JP2019558778A JP2020518571A5 JP 2020518571 A5 JP2020518571 A5 JP 2020518571A5 JP 2019558778 A JP2019558778 A JP 2019558778A JP 2019558778 A JP2019558778 A JP 2019558778A JP 2020518571 A5 JP2020518571 A5 JP 2020518571A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- alkyl
- ring
- independently
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- NJCUGSHOGLOYFF-UHFFFAOYSA-N CC(C)Cc1ccc(C(CC2)CC=C2c2cnc(-c3ccc(CN(CC(O)=O)C(c(cc4)ccc4NC(Cc(cc4)c(C(F)(F)F)cc4OC)=O)=O)cc3)nc2)cc1 Chemical compound CC(C)Cc1ccc(C(CC2)CC=C2c2cnc(-c3ccc(CN(CC(O)=O)C(c(cc4)ccc4NC(Cc(cc4)c(C(F)(F)F)cc4OC)=O)=O)cc3)nc2)cc1 NJCUGSHOGLOYFF-UHFFFAOYSA-N 0.000 description 2
- XBZOBROMNOVPDV-UHFFFAOYSA-N CCCCCC(CC1)CCC1C(CC1)CC=C1c1cnc(-c2ccc(CN(CC(O)=O)C(c(cc3)ccc3NC(Cc(cc3)c(C(F)(F)F)cc3OC)=O)=O)cc2)nc1 Chemical compound CCCCCC(CC1)CCC1C(CC1)CC=C1c1cnc(-c2ccc(CN(CC(O)=O)C(c(cc3)ccc3NC(Cc(cc3)c(C(F)(F)F)cc3OC)=O)=O)cc2)nc1 XBZOBROMNOVPDV-UHFFFAOYSA-N 0.000 description 2
- NZLZPEXQNSVHJE-UHFFFAOYSA-N CC(C)(C)C(CC1)CC=C1c1cnc(-c2ccc(CN(CC(O)=O)C(c(cc3)ccc3NC(Cc(cc3)ccc3OC)=O)=O)cc2)nc1 Chemical compound CC(C)(C)C(CC1)CC=C1c1cnc(-c2ccc(CN(CC(O)=O)C(c(cc3)ccc3NC(Cc(cc3)ccc3OC)=O)=O)cc2)nc1 NZLZPEXQNSVHJE-UHFFFAOYSA-N 0.000 description 1
- HHNDFWVUGYHISZ-UHFFFAOYSA-N CC(C)(CC1)CC=C1c1cnc(-c2ccc(CN(CC(O)=O)C(c(cc3)ccc3NC(Cc(cc3)c(C(F)(F)F)cc3OC)=O)=O)cc2)nc1 Chemical compound CC(C)(CC1)CC=C1c1cnc(-c2ccc(CN(CC(O)=O)C(c(cc3)ccc3NC(Cc(cc3)c(C(F)(F)F)cc3OC)=O)=O)cc2)nc1 HHNDFWVUGYHISZ-UHFFFAOYSA-N 0.000 description 1
- SDZSSGGMKDCXRP-UHFFFAOYSA-N CC(C)C(CC1)CC=C1c1cnc(-c2ccc(CN(CC(O)=O)C(c(cc3)ccc3NC(Cc(cc3)c(C(F)(F)F)cc3OC)=O)=O)cc2)nc1 Chemical compound CC(C)C(CC1)CC=C1c1cnc(-c2ccc(CN(CC(O)=O)C(c(cc3)ccc3NC(Cc(cc3)c(C(F)(F)F)cc3OC)=O)=O)cc2)nc1 SDZSSGGMKDCXRP-UHFFFAOYSA-N 0.000 description 1
- MOPPEKSIVUKRQS-UHFFFAOYSA-N CCC(CC1)CC=C1c1cnc(-c2ccc(CN(CC(O)=O)C(c(cc3)ccc3NC(Cc(cc3)c(C(F)(F)F)cc3OC)=O)=O)cc2)nc1 Chemical compound CCC(CC1)CC=C1c1cnc(-c2ccc(CN(CC(O)=O)C(c(cc3)ccc3NC(Cc(cc3)c(C(F)(F)F)cc3OC)=O)=O)cc2)nc1 MOPPEKSIVUKRQS-UHFFFAOYSA-N 0.000 description 1
- HEGMTAXNPHIWBZ-UHFFFAOYSA-N CCC(CC1)CCC1C(CC1)CC=C1c1cnc(-c2ccc(CN(CC(O)=O)C(c3nnc(NC(Cc(cc4)ccc4OC)=O)[s]3)=O)cc2)nc1 Chemical compound CCC(CC1)CCC1C(CC1)CC=C1c1cnc(-c2ccc(CN(CC(O)=O)C(c3nnc(NC(Cc(cc4)ccc4OC)=O)[s]3)=O)cc2)nc1 HEGMTAXNPHIWBZ-UHFFFAOYSA-N 0.000 description 1
- FPMIAQREJSIFNC-YOVUVYLBSA-N CC[C@H](CC1)CC[C@@H]1C(CC1)CC=C1c1cnc(-c2ccc(CN(CC(N)=O)C(c(cc3)ccc3NC(Cc(cc3)ccc3OC)=O)=O)cc2)nc1 Chemical compound CC[C@H](CC1)CC[C@@H]1C(CC1)CC=C1c1cnc(-c2ccc(CN(CC(N)=O)C(c(cc3)ccc3NC(Cc(cc3)ccc3OC)=O)=O)cc2)nc1 FPMIAQREJSIFNC-YOVUVYLBSA-N 0.000 description 1
- CQLYURUKAKQHMU-MXHUKOMYSA-N CC[C@H](CC1)CC[C@@H]1C(CC1)CC=C1c1cnc(-c2ccc(CN(CC(NS(C)(=O)=O)=O)C(c(cc3)ccc3NC(Cc(cc3)ccc3OC)=O)=O)cc2)nc1 Chemical compound CC[C@H](CC1)CC[C@@H]1C(CC1)CC=C1c1cnc(-c2ccc(CN(CC(NS(C)(=O)=O)=O)C(c(cc3)ccc3NC(Cc(cc3)ccc3OC)=O)=O)cc2)nc1 CQLYURUKAKQHMU-MXHUKOMYSA-N 0.000 description 1
- ULEFYDDQESKYDR-UZNLYWMJSA-N CC[C@H](CC1)CC[C@@H]1C(CC1)CC=C1c1cnc(-c2ccc(CN(CC(O)=O)C(c(cc3)ccc3NC(Cc(c(OC)cc(OC)c3)c3OC)=O)=O)cc2)nc1 Chemical compound CC[C@H](CC1)CC[C@@H]1C(CC1)CC=C1c1cnc(-c2ccc(CN(CC(O)=O)C(c(cc3)ccc3NC(Cc(c(OC)cc(OC)c3)c3OC)=O)=O)cc2)nc1 ULEFYDDQESKYDR-UZNLYWMJSA-N 0.000 description 1
- PRCIDDKVESOQCM-MXHUKOMYSA-N CC[C@H](CC1)CC[C@@H]1C(CC1)CC=C1c1cnc(-c2ccc(CN(CC(O)=O)C(c(cc3)ccc3NC(Cc(cc3)ccc3N(C)C)=O)=O)cc2)nc1 Chemical compound CC[C@H](CC1)CC[C@@H]1C(CC1)CC=C1c1cnc(-c2ccc(CN(CC(O)=O)C(c(cc3)ccc3NC(Cc(cc3)ccc3N(C)C)=O)=O)cc2)nc1 PRCIDDKVESOQCM-MXHUKOMYSA-N 0.000 description 1
- WDALJAQUDWTWMQ-QCCMBLGWSA-N CC[C@H](CC1)CC[C@@H]1C(CC1)CC=C1c1cnc(-c2ccc(CN(CC(O)=O)C(c(cc3)ccc3NC(Cc(cc3Cl)ccc3OC)=O)=O)cc2)nc1 Chemical compound CC[C@H](CC1)CC[C@@H]1C(CC1)CC=C1c1cnc(-c2ccc(CN(CC(O)=O)C(c(cc3)ccc3NC(Cc(cc3Cl)ccc3OC)=O)=O)cc2)nc1 WDALJAQUDWTWMQ-QCCMBLGWSA-N 0.000 description 1
- SYQBCIVOYOLCIM-OKBFXJRSSA-N CC[C@H](CC1)CC[C@@H]1C(CC1)CC=C1c1cnc(-c2ccc(CN(CC(O)=O)C(c(cc3)nnc3NC(Cc(cc3)ccc3OC)=O)=O)cc2)nc1 Chemical compound CC[C@H](CC1)CC[C@@H]1C(CC1)CC=C1c1cnc(-c2ccc(CN(CC(O)=O)C(c(cc3)nnc3NC(Cc(cc3)ccc3OC)=O)=O)cc2)nc1 SYQBCIVOYOLCIM-OKBFXJRSSA-N 0.000 description 1
- ASURZAULCFYJJD-JFGCXZKZSA-N CC[C@H](CC1)CC[C@@H]1C(CC1)CC=C1c1cnc(-c2ccc(CN(CC(O)=O)C(c(ccc(NC(Cc(c(C(F)(F)F)c3)ccc3OC)=O)c3Cl)c3Cl)=O)cc2)nc1 Chemical compound CC[C@H](CC1)CC[C@@H]1C(CC1)CC=C1c1cnc(-c2ccc(CN(CC(O)=O)C(c(ccc(NC(Cc(c(C(F)(F)F)c3)ccc3OC)=O)c3Cl)c3Cl)=O)cc2)nc1 ASURZAULCFYJJD-JFGCXZKZSA-N 0.000 description 1
- VNEFUMRZFAEGDM-OKBFXJRSSA-N CC[C@H](CC1)CC[C@@H]1C(CC1)CC=C1c1cnc(-c2ccc(CN(CC(O)=O)C(c(ccc(NC(Cc(cc3)ccc3OC)=O)c3Cl)c3Cl)=O)cc2)nc1 Chemical compound CC[C@H](CC1)CC[C@@H]1C(CC1)CC=C1c1cnc(-c2ccc(CN(CC(O)=O)C(c(ccc(NC(Cc(cc3)ccc3OC)=O)c3Cl)c3Cl)=O)cc2)nc1 VNEFUMRZFAEGDM-OKBFXJRSSA-N 0.000 description 1
- MMWPDCXNGLPVBH-UHFFFAOYSA-N COc1cc(C(F)(F)F)c(CC(Nc(cc2)ccc2C(N(CC(O)=O)Cc(cc2)ccc2-c(nc2)ncc2C(CC2)=CCC2C(F)(F)F)=O)=O)cc1 Chemical compound COc1cc(C(F)(F)F)c(CC(Nc(cc2)ccc2C(N(CC(O)=O)Cc(cc2)ccc2-c(nc2)ncc2C(CC2)=CCC2C(F)(F)F)=O)=O)cc1 MMWPDCXNGLPVBH-UHFFFAOYSA-N 0.000 description 1
- QHDCUGAXLGKZJU-YBQHVXFOSA-N COc1ccc(CC(N(CCC2)[C@@H]2C(N(CC(O)=O)Cc(cc2)ccc2-c(nc2)ncc2C(CC2)=CCC2C2CCCCC2)=O)=O)cc1 Chemical compound COc1ccc(CC(N(CCC2)[C@@H]2C(N(CC(O)=O)Cc(cc2)ccc2-c(nc2)ncc2C(CC2)=CCC2C2CCCCC2)=O)=O)cc1 QHDCUGAXLGKZJU-YBQHVXFOSA-N 0.000 description 1
- NLPALMYMHJALJL-UHFFFAOYSA-N COc1ccc(CC(NCC(N(CC(O)=O)Cc(cc2)ccc2-c(nc2)ncc2C(CC2)=CCC2C2CCCCC2)=O)=O)cc1 Chemical compound COc1ccc(CC(NCC(N(CC(O)=O)Cc(cc2)ccc2-c(nc2)ncc2C(CC2)=CCC2C2CCCCC2)=O)=O)cc1 NLPALMYMHJALJL-UHFFFAOYSA-N 0.000 description 1
- GGOYJBFLGLWJFP-UHFFFAOYSA-N COc1ccc(CC(NCCC(N(CC(O)=O)Cc(cc2)ccc2-c(nc2)ncc2C(CC2)=CCC2C2CCCCC2)=O)=O)cc1 Chemical compound COc1ccc(CC(NCCC(N(CC(O)=O)Cc(cc2)ccc2-c(nc2)ncc2C(CC2)=CCC2C2CCCCC2)=O)=O)cc1 GGOYJBFLGLWJFP-UHFFFAOYSA-N 0.000 description 1
- QTZORYHBAZQHRB-UHFFFAOYSA-N COc1ccc(CC(Nc2nnc(C(N(CC(O)=O)Cc(cc3)ccc3-c(nc3)ncc3C(CC3)=CCC3C3CCCCC3)=O)[s]2)=O)cc1 Chemical compound COc1ccc(CC(Nc2nnc(C(N(CC(O)=O)Cc(cc3)ccc3-c(nc3)ncc3C(CC3)=CCC3C3CCCCC3)=O)[s]2)=O)cc1 QTZORYHBAZQHRB-UHFFFAOYSA-N 0.000 description 1
- IOEAJXFOQFKBSL-UHFFFAOYSA-N Cc1cc(OC)ccc1CC(Nc(cc1)ccc1C(N(CC(O)=O)Cc(cc1)ccc1-c(nc1)ncc1C(CC1)=CCC1C1CCCCC1)=O)=O Chemical compound Cc1cc(OC)ccc1CC(Nc(cc1)ccc1C(N(CC(O)=O)Cc(cc1)ccc1-c(nc1)ncc1C(CC1)=CCC1C1CCCCC1)=O)=O IOEAJXFOQFKBSL-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762491892P | 2017-04-28 | 2017-04-28 | |
| US62/491,892 | 2017-04-28 | ||
| PCT/US2018/029597 WO2018200833A1 (en) | 2017-04-28 | 2018-04-26 | Novel glp-1 receptor modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020518571A JP2020518571A (ja) | 2020-06-25 |
| JP2020518571A5 true JP2020518571A5 (https=) | 2021-06-10 |
| JP7116745B2 JP7116745B2 (ja) | 2022-08-10 |
Family
ID=62117189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019558778A Expired - Fee Related JP7116745B2 (ja) | 2017-04-28 | 2018-04-26 | 新規なｇｌｐ－１受容体モジュレーター |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11530205B2 (https=) |
| EP (1) | EP3615524B1 (https=) |
| JP (1) | JP7116745B2 (https=) |
| AU (1) | AU2018260686B2 (https=) |
| CA (1) | CA3060424A1 (https=) |
| ES (1) | ES2937835T3 (https=) |
| WO (1) | WO2018200833A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109503510B (zh) * | 2019-01-03 | 2020-07-03 | 山东大学 | 一种防龋抗菌的噻唑类化合物及其制备方法 |
| GB201908453D0 (en) * | 2019-06-12 | 2019-07-24 | Enterprise Therapeutics Ltd | Compounds for treating respiratory disease |
| IL310377A (en) | 2021-08-30 | 2024-03-01 | Mindrank Ai Ltd | Novel aryl ether substituted heterocyclic compound as glp1r agonist |
| CN114181187A (zh) * | 2021-11-24 | 2022-03-15 | 上海应用技术大学 | 一种4-甲磺酰胺基丁酰胺化合物的制备方法 |
| TW202521533A (zh) | 2023-09-14 | 2025-06-01 | 香港商歌禮製藥(中國)有限公司 | Glp-1r 激動劑及其治療方法 |
| US12291530B1 (en) | 2023-11-24 | 2025-05-06 | Ascletis Pharma (China) Co., Limited | GLP-1R agonist and therapeutic method thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6007417B2 (ja) * | 2011-05-31 | 2016-10-12 | レセプトス エルエルシー | 新規ｇｌｐ−１受容体安定剤および調節剤 |
| AU2012352349B2 (en) | 2011-12-12 | 2017-08-17 | Receptos Llc | Carboxylic acid derivatives comprising four cycles acting as GLP-1 receptor modulators for therapy of diseases such as diabetes |
| CN109867630A (zh) * | 2013-06-11 | 2019-06-11 | 赛尔基因第二国际有限公司 | 新型glp-1受体调节剂 |
| KR101651505B1 (ko) * | 2014-05-02 | 2016-08-29 | 현대약품 주식회사 | 싸이클로 헥센 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물 |
| EP3172199B1 (en) * | 2014-07-25 | 2020-07-01 | Celgene International II Sarl | Pyrimidine derivatives as glp-1 receptor modulators |
| AU2015360364B2 (en) * | 2014-12-10 | 2020-04-30 | Receptos Llc | GLP-1 receptor modulators |
-
2018
- 2018-04-26 ES ES18723347T patent/ES2937835T3/es active Active
- 2018-04-26 JP JP2019558778A patent/JP7116745B2/ja not_active Expired - Fee Related
- 2018-04-26 EP EP18723347.3A patent/EP3615524B1/en active Active
- 2018-04-26 CA CA3060424A patent/CA3060424A1/en active Pending
- 2018-04-26 AU AU2018260686A patent/AU2018260686B2/en not_active Ceased
- 2018-04-26 WO PCT/US2018/029597 patent/WO2018200833A1/en not_active Ceased
- 2018-04-26 US US16/608,134 patent/US11530205B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020518571A5 (https=) | ||
| JP7536064B2 (ja) | 抗癌活性及び抗増殖活性を呈する２－アミノピリミジン－６－オン及び類似体 | |
| JP6907173B2 (ja) | スルファモイル−アリールアミド及びｂ型肝炎の治療のための薬剤としてのその使用 | |
| TWI662027B (zh) | 用於調節泫尼酯（ｆａｒｎｅｓｏｉｄ）ｘ受體之組合物及方法 | |
| JP7016809B2 (ja) | 抗ウイルス剤としての四環式ピリドン化合物 | |
| JP2021523221A5 (https=) | ||
| JP2021534124A5 (https=) | ||
| JP2019031560A5 (https=) | ||
| AU2021285747A1 (en) | LPA receptor antagonists and uses thereof | |
| WO2007049532A1 (ja) | アミノジヒドロチアジン誘導体 | |
| JP2020507589A5 (https=) | ||
| JP2021523159A5 (https=) | ||
| JP2020525513A (ja) | 癌および他の疾患を治療するためのａｔｆ４阻害剤としてのｎ−（３−（２−（４−クロロフェノキシ）アセトアミドビシクロ［１．１．１］ペンタン−１−イル）−２−シクロブタン−１−カルボキサミド誘導体および関連化合物 | |
| JP2020506951A5 (https=) | ||
| CN107709306A (zh) | Nrf2调节剂 | |
| JP2018518537A5 (https=) | ||
| WO2016041489A1 (zh) | 一种吲哚胺-2,3-双加氧酶抑制剂及其制备方法 | |
| JP2021529814A (ja) | 化学化合物 | |
| JP2020535165A5 (https=) | ||
| TWI870449B (zh) | 吡唑化合物，其配製物以及使用該化合物和/或配製物之方法 | |
| KR20240005892A (ko) | Lpa 수용체 길항제 및 이의 용도 | |
| JP2023532298A (ja) | 化合物、組成物及び方法 | |
| CN111655678A (zh) | 细胞凋亡信号调节激酶-1抑制剂及其应用 | |
| JP2013542267A5 (https=) | ||
| JP2021521178A5 (https=) |